In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bayer: Out of Trouble Come Opportunities

Executive Summary

Bayer's respiratory diseases spin-out Aerovance shows how new opportunities are springing out of Europe's mid-sized firms, many of which are in transition.

You may also be interested in...



Aerovance Raises $38 Million; Plans To Partner Phase IIb Asthma Drug In 2010

Financing will fund Phase IIb studies and formula enhancements for uncontrolled asthma compound; expects to partner drug in 2010.

Movetis Takes GI from J&J

VCs love a part-baked start-up, and one of the best places to find them is within Big Pharma. So it was that Belgium-based Movetis NV raised a record €49 million ($63.4 million) A round in January with a bunch of gastrointestinal-focused assets from Johnson & Johnson.

Specialty Pharma: Tapping Japan

Economic recovery, pharmaceutical consolidation, and a burgeoning private equity sector have encouraged a new cluster of Japan-focused specialty pharmas

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

CO200859

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel